Financial Daily from THE HINDU group of publications
Wednesday, Jun 23, 2004

Cross Currency

Group Sites

Corporate - Announcements

Ranbaxy gets US FDA approval for diabetic drug

Our Bureau

Mumbai , June 22

DRUG company Ranbaxy Laboratories Ltd said on Tuesday that its anti-diabetic drug has got the final approval from regulatory authorities in the US.

The US Food and Drug Administration (US FDA) has given Ranbaxy the green signal to market Metformin Hydrochloride Extended-release Tablets, 500 mg, said a company release.

The approval came after Barr Laboratories Inc, a wholly-owned subsidiary of Barr Pharmaceuticals Inc, selectively waived its rights to exclusivity in favour of Ranbaxy.

Bristol Myers Squibb (BMS) is the original patent holder of the anti-diabetic drug that it sells under the brandname `Glucophage XR Tablets.'

Regulatory authorities in the US have found Ranbaxy's version of the drug to be bio-equivalent to BMS's drug, besides having the same therapeutic effect.

Total sales for the Metformin Extended-release formulation is $363 million, industry sources said.

More Stories on : Announcements | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Electrolux to invest in R&D centre — To source IT services, components from India

Biocon Cuban venture adds 3 cancer vaccines
Ranbaxy gets US FDA approval for diabetic drug
LG, Kodak in pact for camera phone prints
Dishman Pharma debt issue closes
BPCL staff stay away from work
FT picks up 13.85 pc in Business Standard
DHL set to acquire 100 pc stake in Indian operations
Hind Zinc plans to expand lead smelter capacity
ONGC eyes crude, gas shipping biz
Art d'inox targets Rs 30 cr in revenues
ONGC: A disappointing show
NDTV turns cash positive in Q4
Pichai to head Ma Foi tech division

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line